3rd Gene Therapy for Ophthalmic Disorders 2022

The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

Join 40+ speakers from the industry leaders in ophthalmic gene therapy such as: Adverum, REGENXBIO, Novartis, Janssen, Kriya, Nanoscope, IVERIC, GenSight, SparingVision, Atsena, AGTC, ViGeneron and many more as we discover novel vector engineering, disease models, clinical trials design, patient enrolment platforms and more.

This year an additional day to compliment the scientific program has been added. The NEW hotly anticipated post-conference delivery day will address the devices and technology involved in the delivery of these drugs. Additionally, our beloved pre-conference workshop day now has four thought-provoking workshops, covering topics that lend better to longer, more interactive discussions such as: non-viral modalities & US & EU regulatory considerations.

Join 150+ stake holders within the industry to overcome these challenges and get these drugs to the ophthalmic gene therapy patients who needs them as fast as possible.

Group discounts and early booking rates are available. Please visit the website for full pricing information.